Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Gilead Sciences logo
Gilead SciencesGILD
$2.43B+46.8%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$33.53M+10.8%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$12.92M+75.6%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$9.86M-462%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Calculated from Artiva Biotherapeutics, Inc.’s reported figures.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s free cash flow?
Artiva Biotherapeutics, Inc. (ARTV) reported free cash flow of -$21.19M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s free cash flow changed year-over-year?
Artiva Biotherapeutics, Inc.'s free cash flow decreased by 4.1% year-over-year, from -$20.35M to -$21.19M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.